Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752330 | 0.83 | HTR2A (0.40) | MAPTALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL15031956 | 0.83 | HTR2A (0.40) | MAPTALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL27050520 | 0.82 | AHR (0.33) | AKR1B1 | |
| SCHEMBL27050573 | 0.78 | AHR (0.33) | AKR1B1 | |
| SCHEMBL15250372 | 0.75 | PPARG (0.45) | MAPTTDP1SLC6A4KCNH2MRGPRX4 | |
| SCHEMBL19088272 | 0.72 | KDM1A (0.40) | MAPTALDH1A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL12885399 | 0.71 | PPARG (0.42) | MAPTALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL14664865 | 0.71 | SOS1 (0.44) | MAPTALDH1A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL14884524 | 0.70 | CA3 (0.43) | ALDH1A1 | |
| SCHEMBL12157430 | 0.70 | TRPA1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | MAPT 4520/4885ALDH1A1 2152/4885TDP1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.